Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Reports Share Transfer and Gift
SEC Form 4 Filing
CEO Samarth Kulkarni reports a gift of 100,000 common shares and a transfer of shares from a GRAT.
Summary
- On August 8, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics AG, reported a transaction involving the company's common shares.
- Kulkarni gifted 100,000 common shares.
- Additionally, 114,378 shares were transferred from the Kulkarni 2023 GRAT to Kulkarni.
- Following these transactions, Kulkarni directly owns 222,500 common shares and indirectly owns 85,622 common shares through the Kulkarni 2023 GRAT.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of gift of 100,000 common shares and transfer of shares from Kulkarni 2023 GRAT. |
| 08/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.